Failure To Update Invalidates Evaluation And Responsibility Determination
Client Alert | less than 1 min read | 02.17.06
In Greenleaf Constr. Co. (Jan. 17, 2006, http://www.gao.gov/decisions/bidpro/29310518.pdf), GAO held that the awardee's failure to advise the agency of changes to its proposed plan for performance which arose after submission of its final proposal revision, including different key personnel and a different software system, invalidated the technical evaluation based on the original proposal. GAO also invalidated the contracting officer's responsibility determination as to the adequacy of awardee's financial resources because the contracting officer knew that an affiliated company that had provided most of the revenues of the awardee's corporate family in the DCAA analysis had been sold.
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26
